Kakoki et al 1 recently reported a reduced endothelin (ET) B receptor-mediated release of nitric oxide (NO) in renal perfusates of experimental models of hypertension, diabetes mellitus, and hypercholesterolemia, as measured by H 2 O 2 -based chemiluminescence. Reduced immunostaining for endothelial ET B receptors, as measured by semiquantitative immunohistochemistry, was observed in all experimental models, whereas staining for endothelial NO synthase (eNOS) was reduced in salt-sensitive Dahl rats but not spontaneously hypertensive (SHR) or hypercholesterolemic rats. Although interesting, these observations must be interpreted with caution.
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We would like to thank Drs Barton and d'Uscio for their thoughtful comments on our article. Most pharmacological studies have suggested a normal or somehow increased release of nitric oxide (NO) in spontaneously hypertensive rats (SHR). 1, 2 We have measured the NO released from isolated kidneys in 4 different series of SHR and Wistar Kyoto rats since 1993 and have confirmed our results. 3 We and others have shown that the attenuated response of uncomplicated SHR to endotheliumdependent vasodilators is due to a decrease in an endotheliumderived hyperpolarizing factor rather than to a decrease in NO itself. 3 We suggested that increased endothelin (ET)-1 downregulated the expression of the ET type B receptor (ETBR). Therefore, we measured ET-1 levels in the plasma of Dahl rats. As mentioned, our assay system may detect NO from the tubuli and macula densa as well as that from the vascular endothelium. However, the response of the NO signal to acetylcholine or BQ-3020 was very rapid and was not influenced by pretreatment with 7-nitroindazole, a neuronal NO synthase inhibitor, which suggests that most of the signal reflects endothelium-derived NO.
ETBR stimulation acts on both endothelial cells and vascular smooth muscle cells (VSMCs) and results in contrasting effects on vascular tone (ie, vasodilation and vasoconstriction in each type of cell, respectively). Changes in vascular tone induced by BQ-3020 are determined by the balance of NO release and its effects on VSMCs. The most important observation in our article, we believe, is that relatively low doses of BQ-3020 dilated normal vessels, while the same levels constricted vessels from rats with hypertension, diabetes mellitus, or hypercholesterolemia. However, the increased vasoconstrictive response in diseased animals is probably due to both reduced NO release and increased vasoconstrictive activity. Because we infused BQ-3020 intra-arterially, it is possible that BQ-3020 easily reached the endothelium, even at low doses. Higher doses of BQ-3020 may be required to stimulate ETBR in VSMCs. However, because the perfusate contained indomethacin, it is unlikely that prostacyclin was the major factor accounting for differences in vascular responses to BQ-3020.
It is still controversial as to whether ET type A receptor (ETAR) antagonists or ETAR/ETBR antagonists are beneficial for cardiovascular damage. It is clear that ETAR antagonists are beneficial in various pathological situations. Furthermore, a blockade of ETBR constricts normal vessels. The comparative study by Matsumura et al 4 showed the superiority of an ETAR antagonist over ETAR/ETBR antagonists in the treatment of deoxycorticosterone acetate-salt hypertension. However, the rats used showed borderline hypertension and their endothelial damage was probably minimal. In this situation, a blockade of ETBR may result in vasoconstriction and worsen the hypertensive tissue damage. However, Cardillo et al 5 
